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ABSTRACT 
Arterioles (200 to 400 J.L in outer diameter) from dog and human skin were studied in vitro 
to measure changes in tension induced by prostaglandin E 2 (PGE2) alone and in 
combination with catecholamines. The effects of sympathetic blocking drugs and of calcium 
on vessel response to PGE2 were also studied. PGE2 caused contraction of both the dog and 
human vessels, with evident differences in frequency of response. PGE2 also increased the 
magnitude of vessel response to a given dose of epinephrine or norepinephrine, in addition to 
lowering the threshold level for response to the catecholamines. Alpha blockade and beta 
blockade did not prevent PGE2-induced contraction. The contractile response to PGE2 was 
observed to increase as the calcium concentration of the vessel bath was increased. These 
studies show that, in vitro, the cutaneous arteriolar vascular smooth muscle of the dog and 
the human responds to PGE2 via a pathway other than that of the alpha receptor. However, 
alpha-receptor response can be modified by PGE2. Thus, prostaglandins may mediate 
cutaneous vascular activity not only through their own effect but also by modifying 
responses to catecholamines. 
Within the past five years, studies have re-
ported the isolation of prostaglandins from frog 
skin and prostaglandin-like substances from the 
inflamed skin of dogs and humans [1-3]. The 
ability of rat skin and human skin to synthesize 
and metabolize mainly E prostaglandins has been 
reported by Ziboh and Hsia [4 ], by Greaves and 
McDonald-Gibson [5 ], and by Jonsson and Ang-
gard [6] using skin homogenates. More recently, 
Mathur and Gandhi [7] reported the presence of 
PGE in human and albino rat skin as well as an 
increase in tissue PGE after ultraviolet irradiation 
of the skin. These studies, while not conclusive, 
strongly support a role for PGE2 in cutaneous 
physiology and pathology, and in this context the 
effects of PGE2 on cutaneous vasculature and on 
vascular smooth muscle in general become impor-
tant. 
The vasoactive properties of the prostaglandins 
are well documented, as is their presence in many 
tissues and organs in animals and in humans [8 ]. 
As a group, the E prostaglandins lower the blood 
pressure when injected intravenously in dogs and 
man [9, 10 ]. Some studies suggest that this effect 
results from direct vascular dilatation [11-13 ]. 
However, qualitative and quantitative differences 
in response occur among different species as well 
as among different parts of the cardiovascular 
system [14, 15 ]. 
The present study was undertaken to document 
the in vitro effects of prostaglandin E2 (PG E2) on 
cutaneous arterioles of the dog and of man, the 
interaction of PGE2 with catecholamines, and the 
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effects of PGE2 m the presence of sympathetic 
blocking drugs. 
MATERIALS AND METHODS 
Arterioles (200-400 1-L in outer diameter) from the skin 
of the paw, back, and ear of the dog and from the breast 
and finger of the human were dissected into continuous 
helical strips and doughnut-shaped transverse slices. 
According to the method of Sams and Winkelmann [16] 
modified from that of Strong and Bohr [17 ], these 
arteriolar preparations were suspended in a bath of 
physiologic salt solution of the following composition 
(mM/L): NaCl 119, KCl 4.7, KH2PO. 1.18, MgSO. 4.7, 
NaHC03 14.9, CaCl2 1.6, dextrose 5.5, sucrose 50, and 
EDTA 0.026 (added to prevent oxidation of epineph-
rine). The solution was preoxygenated and maintained 
at a constant temperature of 37° C. The strips and slices 
were vertically suspended by 6-0 surgical silk in the 
physiologic salt solution. One end was tied to an anchor 
point, and the other end was tied to a metal rod 
connected to an isometric tension transducer (Grass 
force-displacement transducer FTO 3C). An ink-writing 
polygraph monitored the isometric tension change of the 
vessels; the vessels were initially stretched to a tension 
(usually 100 mg) that permitted optimal response to 
stimulation. The vessels were tested for viability by 
stimulation with 100 ~-tM KCl, and only vessels that gave 
a contractile response were included in this study. 
Dose-response curves for any given vessel strip could be 
drawn, with the vascular smooth-muscle response to the 
prostaglandin and catecholamines plotted as a percent-
age of the standard stimulation response for that vessel 
strip. 
Because of unavoidable variations in the dimensions 
(therefore, in muscle mass) of individual vessel strips 
and with possible differential trauma inherent in dissec-
tion and preparation of vessels, no reliable interpreta-
tion could be made of the quantitative differences in 
magnitude of contraction between individual vessel 
strips or of the variability in percentages of response. We 
could, however, compare the qualitative responses of a 
given vessel strip to the various vasoactive agents used. 
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These qualitative responses were reproducible and con-
sistent from one vessel strip to another. 
The following studies were undertaken: (1) the cu-
taneous vascular smooth-muscle response to varied 
concentrations of PGE2; (2) the effects of PGE2 on the 
vessel's response to catecholamines; (3) the effects of 
PGE2 in the presence of sympathetic blocking drugs; 
and (4) the effect on the smooth-muscle response to 
~GE2 of varied concentrations of calcium in the vessel 
;ath. The vessels were incubated for 1 hr in each of three 
)athing solutions with respective CaCl2 concentrations 
Jf 0.2, 1.6, and 3.2 mM/L. After this period, a fixed 
concentration of PGE2 was added to the bath, and the 
response was recorded. A dose-response curve was con-
structed to show the influence of calcium on smooth-
muscle response to the prostaglandin. 
The dog vessels were obtained from animals sacrificed 
by exsanguination. Fluothane anesthesia was employed 
in the hospital patients from whom surgical specimens 
served as the source of human vessels. All human vessels 
were incubated in a physiologic salt solution at 4 o C for 
24 hr to ensure the washout of the anesthetic. 
The prostaglandin was obtained in crystalline form 
from Dr. John Pike of the Upjohn Company, Kalama-
zoo, Mich., and was dissolved in 95% ethanol. The 
solution was diluted with a physiologic salt solution 
(CaCl2, 0.2 mM/L for calcium studies) to achieve the 
graded concentrations of PGE2. Control solutions were 
prepared with 95% ethanol and diluted with physiologic 
salt solution. 
RESULTS 
PGE 2 produced contraction of the cutaneous 
arteriolar smooth-muscle strips of both the dog 
and the human, but the number of vessels re-
sponding varied in each group (Table I). In 
response to PGE 2 (lo-s to 10- 5 gm/ml), 32 of 45 
(71 %) dog-paw skin vessel preparations con-
tracted. Regional difference in frequency of re-
sponse was evident inasmuch as 46 of 95 (48%) 
back skin vessels contracted, and 7 of 40 ( 18%) 
dog ear skin vessels contracted. The magnitude 
of response for a given strip increased with in-
creasing concentrations of PGEz (Fig. 1). 
The number of human vessel strips responding 
to PG E 2 alone was low. Only 4 of 40 ( 10%) breast 
vessels and 1 of 8 ( 13%) finger skin vessels 
contracted. Relaxation of smooth muscle by PGE 2 
in the dose range (l0- 9 to w- 5 gm/ml) studied did 
not occur in either the dog or the human vessel 
strips, even when the vessels were actively con-
tracted by KCl or epinephrine prior to the addi-
tion of PGE 2 • In fact, vasoactive doses of PGE 2 
raised the tension level of a previously induced 
catecholamine or KCl contraction. 
Nonvasoactive (subthreshold) doses of PGE 2 
increased the magnitude of contraction of the 
vessel strips to a given vasoactive dose of epineph-
rine or norepinephrine (Fig. 2). This potentiation 
occurred whether the prostaglandin was intro-
duced before or after the catecholamine. A poten-
tiated response to epinephrine was elicited in 32 of 
40 ( 80%) dog ear vessels and in 36 of 40 (90%) paw 
vessels. A characteristic dose-response curve is 
illustrated (Fig. 3). In addition, the dose-response 
threshold to the catecholamines was lowered sig-
TABLE I 
Summary of regional cutaneous vascular smooth-muscle 
contractile responses to prostaglandin E2 in dog and in 
human arterioles 
Skin vessel 
Paw 
Back 
Ear 
Breast 
Finger 
No. of vessel 
strips 
Dog 
45 
95 
40 
Human 
40 
8 
400 1J diameter vessel 
% 
32 71 
46 48 
7 18 
4 10 
13 
Wash Wash Wash 
I I I 
~~~
I I I 
6 XI0-6 IX 10-5 2xl0-5gm/ml 
PGE 2 PGE 2 PGE2 
FIG. 1. Dog-paw arteriole response to prostaglandin 
E2 demonstrating dose dependency. 
Dog paw artery strip 
400~ 
t 
2x10-9 gm/ml 
Norepinephrine 
I20mg 
1-----j 1 min 
~ 
.5ml 2 xl0-9 gm/ml 
PSS Norepinephrine 
~rt 
1 x10- 6 2x10-9gm/ml .5ml 2 x10-9gm/ml 
PGE2 -Epinephrine PSS Epinephrine 
FIG. 2. Pote~tiation of dog-paw arteriole response to 
epinephrine and norepinephrine by prostaglandin E 2. 
nificantly by prior exposure to PGE2 , as shown by 
the dose-response curve. Thus, concentrations of 
epinephrine or norepinephrine that did not pro-
duce a vessel response by themselves became 
vasoactive when combined with a subthreshold 
dose of PGE 2 (Fig. 4). This observation is of 
particular interest in regard to the human vessels 
which, although unresponsive to PGE 2 alone, 
showed potentiation by PGE 2 of epinephrine- or 
norepinephrine-induced contractions (Table II). 
Twenty-one of 37 (57%) breast skin vessels and 4 
of 8 (50%) finger skin vessels showed potentiated 
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FIG. 3. Dose-response curve showing potentiation by 
prostaglandin E 2 of dog-paw arteriole contraction to 
epinephrine. 
Human 400p finger arterial strip 
I 20mg 
~1min 
Wash 
t t t 
Wash 
2xlo-9 4xlo-7 2x10-9 gm/ml 
Epinephrine PGE2 Epinephrine 
FIG. 4. Contraction of human finger skin arterial 
strip by subthreshold dose of epinephrine after prior 
exposure of vessel to subthreshold dose of prostaglandin 
E2. 
TABLE II 
Summary of potentiated epinephrine responses to 
prostaglandin E 2 in dog and in human cutaneous 
arterioles 
Skin vessel 
Ear 
Paw 
Breast 
Finger 
No. of 
preparations 
Dog 
40 
40 
Human 
37 
8 
% 
32 80 
36 90 
21 57 
4 50 
catecholamine responses after exposure to PGE2. 
The contractile response to PGE2 was not al-
tered in the presence of sympathetic blocking 
drugs (Fig. 5). Phentolamine, at concentrations of 
5 X w- 6 and 5 X w- 5 gm/ml, did not inhibit PEG2-
induced smooth-muscle contractions or alter the 
magnitude of the contraction in comparison to a 
preblocking control. However, contractions in-
duced by epinephrine (2 x 10- 7 gm/ml) and by 
norepinephrine (2 x 10- 7 gm/ml) were completely 
abolished at a blocking dose of 5 X 10- 6 gm/ml. 
Prior addition of propranolol (5 x l0- 6 gm/ml) 
had no effect on subsequent response of the vessels 
to PGE2. 
The contraction of the vessel strips by PGE2 was 
dependent on calcium concentration, as shown by 
an increasing magnitude of contraction to a given 
dose of PGE2 when the calcium concentration in 
the vessel bath was increased. A dose-response 
curve for seven dog-paw vessel strips is shown 
(Fig. 6). Comparisons of the increments in tension 
occurring between 0.2 and 1.6 mM/L of calcium 
and between 1.6 and 3.2 mM/L of calcium reveal 
statistically significant changes (P < 0.05 and P 
< 0.025, respectively). 
DISCUSSION 
Previous studies [1, 14, 18-21] have demon-
strated the in vitro synergism between prosta-
glandins and catecholamines in nonvascular and 
vascular smooth muscle as well as the effect of 
calcium on the response to prostaglandins and the 
lack of dependence on the alpha receptor for the 
prostaglandin effect. There is, in fact, evidence to 
400 u diameter vessels 
~ rsm;,J\ 
I I -t- I I 
4•10- 6 Wash 5x 10-6 4•1o- 6 gm/ml Wash 
PG E 2 PR0fo~ AN - PGE 2 
FIG. 5. Effects of prostaglandin E2 on dog-paw artery 
response before and after exposure of vessels to phen-
tolamine or propranolol. 
1 2 3 4 
Concentration of calcium (mM/L) 
FIG. 6. Dose-response curve showing increased mag-
nitude of dog-paw (seven strips) arteriolar contraction to 
fixed concentration of prostaglandin E 2 (lQ - 2 mg/ml) as 
calcium concentration of vessel bath is increased. 
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suggest that specific membrane receptors for pros-
taglandins exist [22, 23 ]. 
In vivo studies have, in contrast to those in 
vitro, generally demonstrated a vasodilator re-
sponse to the E prostaglandins. Bergstrom et al 
[9 ], Carlson and Oro [24], and Steinberg and 
Pittman [25] produced vasodilation after intrave-
nous or intra-arterial administration of PGE1, as 
measured by a decrease in perfusion pressure of 
the vascular segment under investigation. In addi-
tion, PGE1 antagonized the catecholamine vaso-
constriction. Solomon et al [26] observed severe 
local erythema after the intradermal injection of 
PGE1 in humans, guinea pigs, and rabbits. Simi-
lar results were reported by Crunkhorn and Willis 
[27]. 
The differences noted between in vivo and in 
vitro responses to the E prostaglandins may stem 
from the caliber of vessels studied in each in-
stance. In vitro techniques require larger-caliber 
vessels which may, by nature of regional differen-
tiation, respond differently than smaller terminal 
arterioles and capillaries. Regional specificity of 
response is supported by both in vivo and in vitro 
studies. Stovall and Jackson [28] and Anggard 
[29] reported in vivo vasoconstriction of nasal 
mucosal vessels in dogs and humans. Strong and 
Bohr [17] demonstrated that, in vitro, muscular, 
mesenteric, and renal arterioles from dogs showed 
a biphasic response to PGE2 with relaxation at low 
doses and contraction at higher doses, whereas 
isolated aorta and coronary artery strips of the 
rabbit demonstrated only contraction at all dose 
levels of PGE2. 
Another possible explanation for the diversity of 
observations is that, in vivo, the prostaglandins 
may be only one of several substances that influ-
ence the final response of a given vascular bed, as 
suggested by recent studies of Crunkhorn and 
Willis [27 ]. 
Whatever the specific pathway of action of 
prostaglandins on cutaneous vascular smooth 
muscle-studies show an intimate relationship 
between prostaglandins and cyclic AMP [30, 
31 ]-this study demonstrates that PGE2 can act 
as a significant modulator of vascular smooth-
muscle activity, both by itself and by affecting the 
response to catecholamines. The blocking studies 
are consistent with the concept of a separate 
prostaglandin receptor. 
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